Multicomponent Pharmaceutical Solids

Pharmaceutical Solids — The Amorphous Phase

“Pharmaceutical Solids” discusses scientific principles associated with pharmaceutical solids useful to practitioners in validation and compliance. We intend this column to help the understanding of principles associated with pharmaceutical solids and to be a useful resource for daily work applications. Enhanced process understanding is an important objective of the quality-by-design initiative...

Protic pharmaceutical ionic liquids and solids: aspects of protonics.

A series of new protic compounds based on active pharmaceutical ingredients have been synthesised and characterised. Some of the salts synthesised produced ionic liquids, while others that were associated with rigid molecular structures tended to produce high melting points. The "protonic" behaviour of these compounds was found to be a major determinant of their properties. Indicator studies, F...

Pharmaceutical Salts: Solids to Liquids by Using Ionic Liquid Design

Particle Engineering in Pharmaceutical Solids Processing: Surface Energy 
Considerations

During the past 10 years particle engineering in the pharmaceutical industry has become a topic of increasing importance. Engineers and pharmacists need to understand and control a range of key unit manufacturing operations such as milling, granulation, crystallisation, powder mixing and dry powder inhaled drugs which can be very challenging. It has now become very clear that in many of these p...

Can computed crystal energy landscapes help understand pharmaceutical solids?

Computational crystal structure prediction (CSP) methods can now be applied to the smaller pharmaceutical molecules currently in drug development. We review the recent uses of computed crystal energy landscapes for pharmaceuticals, concentrating on examples where they have been used in collaboration with industrial-style experimental solid form screening. There is a strong complementarity in ai...